6/28/23, 11:08 PM Hi-Light Vitiligo Pathway Feedback Search Clinical Topics Home Studies Hi-Light Vitiligo Hi-Light Vitiligo Disease Vitiligo Trial question Is combination treatment with narrowband UV-B light plus topical corticosteroids superior to topical corticosteroids alone in patients with vitiligo? Study design Multi-center Double blinded RCT Population Characteristics of study participants 48.0% female N = 348 52.0% male 348 patients (168 female, 180 male) Inclusion criteria: adults and children with active vitiligo affecting < 10% of skin Key exclusion criteria: segmental or universal vitiligo; vitiligo limited to areas contraindicated for treatment with potent topical corticosteroid or evidence of marked Koebner phenomenon; history of skin cancer; radiotherapy use or photosensitivity; pregnancy Interventions N=175 combination therapy (topical corticosteroid ointment plus narrowband UV-B light) N=173 topical corticosteroid (topical corticosteroid plus dummy narrowband UV-B light) Primary outcome Target patch treatment success at 9 months 27.0 % 27 https://web.pathway.md/studies/recb7FleffsCYpOz1 1/2 6/28/23, 11:08 PM Hi-Light Vitiligo Pathway 20.3 % 17 13.5 % Significant increase 6.8 % NNT = 10 0.0 % Combination therapy Topical corticosteroid Significant increase in target patch treatment success at 9 months (27% vs. 17%; OR 1.93, 95% CI 1.02 to 3.68) Secondary outcomes Borderline significant increase in treatment success as assessed by blinded patient and public involvement assessors at 9 months (28% vs. 11%; OR 3.52, 95% CI 1.8 to 6.89) Borderline significant increase in repigmentation as assessed by blinded dermatologist using digital images of target patch at 9 months (15% vs. 3%; OR 4.62, 95% CI 1.5 to 14.2) Conclusion In adults and children with active vitiligo affecting < 10% of skin, combination therapy was superior to topical corticosteroid with respect to target patch treatment success at 9 months. Reference K S Thomas, J M Batchelor, P Akram et al. Randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo: results of the HI-Light Vitiligo Trial. Br J Dermatol. 2021 May;184(5):828-839. Open reference URL https://web.pathway.md/studies/recb7FleffsCYpOz1 2/2